RECTOSIGMOID CANCER RECURRENT

This adverse event was reported 8 times

These drugs are most commonly taken by patients reporting RECTOSIGMOID CANCER RECURRENT:

# Drug Count
0 LETROZOLE 3
1 LETROZOLE TABLETS 3
2 PALBOCICLIB 3
3 OXALIPLATIN 2
4 PACLITAXEL 2
5 PACLITAXEL (AIBUMIN-BOUND) 2
6 BEVACIZUMAB 1
7 CAPECITABINE 1
8 CETUXIMAB 1
9 DICLOFENAC SODIUM 1
See all common drugs associated with RECTOSIGMOID CANCER RECURRENT

RECTOSIGMOID CANCER RECURRENT is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 ZIV-AFLIBERCEPT 1 0.0008
1 LETROZOLE TABLETS 3 0.0001
2 LETROZOLE 3 0.0000
3 CETUXIMAB 1 0.0000
4 PALBOCICLIB 3 0.0000
5 OXALIPLATIN 2 0.0000
6 METHADONE 1 0.0000
7 PACLITAXEL 2 0.0000
8 FLUOROURACIL CREAM, 0.5% 1 0.0000
9 FLUOROURACIL 1 0.0000
See all drugs enriched for association with RECTOSIGMOID CANCER RECURRENT

RECTOSIGMOID CANCER RECURRENT is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Aromatase Inhibitor [EPC] 3 0.0000
1 Epidermal Growth Factor Receptor Antagonist [EPC] 1 0.0000
2 Microtubule Inhibitor [EPC] 2 0.0000
3 Platinum-based Drug [EPC] 2 0.0000
4 Vascular Endothelial Growth Factor Inhibitor [EPC] 1 0.0000
5 Kinase Inhibitor [EPC] 3 0.0000
6 Nucleoside Metabolic Inhibitor [EPC] 1 0.0000
7 Vitamin D [EPC] 1 0.0000
8 Vitamin B12 [EPC] 1 0.0000
9 Vitamin C [EPC] 1 0.0000
See all drug classes enriched for association with RECTOSIGMOID CANCER RECURRENT